TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Denver's Democratic National Convention Last year's Democratic National Convention, Aug. 25-28, was a time for Denver to shine on the national stage as never before. And the local business community played a major part in pulling off one of the largest events in the city's history. feeds.bizjournals.com |
Health-Care Negotiators Pare Costs Senate negotiators say they have cut the cost of their 10-year health-coverage plan to under $880 billion. online.wsj.com |
FDA Narrowly Clears Melanoma Drug An FDA panel narrowly backed the use of Schering Plough's Pegintron in patients with advanced melanoma amid concerns about drug side-effects. online.wsj.com |
A 130 / 30 Global Pharma Strategy Mike Havrilla submits:Investors who are bullish on the generic drug industry may consider implementing a 130 / 30 global pharma investing strategy through equal-weight (5% each) short positions for the six brand drug companies outlined below with 30% of their assets while investing 130% of assets in long positions among generic drug makers. The list of brand drug companies with significant patent expiration exposure over the next 2-3 years includes Pfizer (NYSE: PFE), GlaxoSmithKline (NYSE: GSK), Takeda Pharma (OTC: TKPHY.PK), Sanofi-Aventis (SNY), AstraZeneca (AZN), and Merck (MRK). The HavRx Global Generic Drug Index is actively managed and tracks the performance of companies which meet any of the following three requirements:Complete Story » seekingalpha.com |
Celgene to Acquire Gloucester Pharma Celgene agreed to acquire privately held drug maker Gloucester Pharmaceuticals for $340 million plus milestone payments of up to $300 million in a deal to bolster its position in blood-cancer treatments. online.wsj.com |